GSK receives EU marketing authorisation for Incruse (umeclidinium) for the treatment of COPD

GlaxoSmithKline plc (LSE/NYSE: GSK) announced today that the European Commission has granted marketing authorisation for Incruse® (umeclidinium) as a once-daily, maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
Source: GSK news - Category: Pharmaceuticals Source Type: news